| Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area CM Booth, LM Matukas, GA Tomlinson, AR Rachlis, DB Rose, HA Dwosh, ... Jama 289 (21), 2801-2809, 2003 | 1881 | 2003 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 1209 | 2020 |
| Functional variants of OCTN cation transporter genes are associated with Crohn disease VD Peltekova, RF Wintle, LA Rubin, CI Amos, Q Huang, X Gu, B Newman, ... Nature genetics 36 (5), 471-475, 2004 | 984 | 2004 |
| Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression IS Harris, AE Treloar, S Inoue, M Sasaki, C Gorrini, KC Lee, KY Yung, ... Cancer cell 27 (2), 211-222, 2015 | 915 | 2015 |
| Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ... Annals of Oncology 30 (3), 397-404, 2019 | 699 | 2019 |
| Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study S Adams, S Loi, D Toppmeyer, DW Cescon, M De Laurentiis, R Nanda, ... Annals of Oncology 30 (3), 405-411, 2019 | 536 | 2019 |
| CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours H Xu, M Di Antonio, S McKinney, V Mathew, B Ho, NJ O’Neil, ND Santos, ... Nature communications 8 (1), 14432, 2017 | 471 | 2017 |
| Circulating tumor DNA and liquid biopsy in oncology DW Cescon, SV Bratman, SM Chan, LL Siu Nature Cancer 1 (3), 276-290, 2020 | 371 | 2020 |
| Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer J Cortes, HS Rugo, DW Cescon, SA Im, MM Yusof, C Gallardo, O Lipatov, ... New England Journal of Medicine 387 (3), 217-226, 2022 | 364 | 2022 |
| BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival C Gorrini, PS Baniasadi, IS Harris, J Silvester, S Inoue, B Snow, PA Joshi, ... Journal of Experimental Medicine 210 (8), 1529-1544, 2013 | 302 | 2013 |
| Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2 S Inoue, WY Li, A Tseng, I Beerman, AJ Elia, SC Bendall, F Lemonnier, ... Cancer cell 30 (2), 337-348, 2016 | 206 | 2016 |
| KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab+ chemotherapy versus placebo+ chemotherapy for previously untreated locally recurrent inoperable or … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... Journal of Clinical Oncology 38 (15_suppl), 1000-1000, 2020 | 198 | 2020 |
| Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086 S Loi, S Adams, P Schmid, J Cortés, DW Cescon, EP Winer, ... Annals of Oncology 28, v608, 2017 | 190 | 2017 |
| Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent JM Mason, DCC Lin, X Wei, Y Che, Y Yao, R Kiarash, DW Cescon, ... Cancer cell 26 (2), 163-176, 2014 | 182 | 2014 |
| Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ... Journal of Clinical Oncology 35 (15_suppl), 1008-1008, 2017 | 169 | 2017 |
| GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer Q Wu, W Ba-Alawi, G Deblois, J Cruickshank, S Duan, E Lima-Fernandes, ... Nature communications 11 (1), 4205, 2020 | 167 | 2020 |
| If we build it they will come: targeting the immune response to breast cancer ME Gatti-Mays, JM Balko, SR Gameiro, HD Bear, S Prabhakaran, J Fukui, ... NPJ breast cancer 5 (1), 37, 2019 | 167 | 2019 |
| Evolution of the randomized controlled trial in oncology over three decades CM Booth, DW Cescon, L Wang, IF Tannock, MK Krzyzanowska Journal of Clinical Oncology 26 (33), 5458, 2008 | 166 | 2008 |
| Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis H Goldvaser, TA Barnes, B Šeruga, DW Cescon, A Ocaña, D Ribnikar, ... JNCI: Journal of the National Cancer Institute 110 (1), 31-39, 2018 | 163 | 2018 |
| Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1 C Roux, SM Jafari, R Shinde, G Duncan, DW Cescon, J Silvester, MF Chu, ... Proceedings of the National Academy of Sciences 116 (10), 4326-4335, 2019 | 156 | 2019 |
